Rony Gelman1, Szilard Kiss, Stephen H Tsang. 1. *Department of Ophthalmology, University of Southern California, Los Angeles, California; †Edward S. Harkness Eye Institute, College of Physicians and Surgeons, Columbia University, New York, New York; ‡Deparment of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York; §Department of Ophthalmology, Weill Cornell Medical College, New York, New York; and ¶Barbara and Donald Jonas Laboratory of Stem Cell and Regenerative Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.
Abstract
PURPOSE: To report a case of deferoxamine-induced maculopathy and present the use of multimodal retinal imaging to study this disease entity. METHODS: This is an observational case report of one patient. Multimodal imaging with fundus autofluorescence, infrared imaging, and spectral domain optical coherence tomography was used to investigate the macular changes induced by deferoxamine toxicity. RESULTS: A 53-year-old man with history of β-thalassemia presented with decreased vision in both eyes 1 month after initiating deferoxamine therapy. Infrared imaging showed areas of increased stippled infrared intensity through the macula. Fundus autofluorescence revealed diffuse areas of stippled hyperautofluorescence and hypoautofluorescence. Spectral domain optical coherence tomography changes included disruption of the ellipsoid zone, attenuation of the photoreceptors, and deposits within the retinal pigment epithelium. CONCLUSION: A case of deferoxamine-induced maculopathy was described and the use of multimodal retinal imaging to study this disease entity was presented.
PURPOSE: To report a case of deferoxamine-induced maculopathy and present the use of multimodal retinal imaging to study this disease entity. METHODS: This is an observational case report of one patient. Multimodal imaging with fundus autofluorescence, infrared imaging, and spectral domain optical coherence tomography was used to investigate the macular changes induced by deferoxaminetoxicity. RESULTS: A 53-year-old man with history of β-thalassemia presented with decreased vision in both eyes 1 month after initiating deferoxamine therapy. Infrared imaging showed areas of increased stippled infrared intensity through the macula. Fundus autofluorescence revealed diffuse areas of stippled hyperautofluorescence and hypoautofluorescence. Spectral domain optical coherence tomography changes included disruption of the ellipsoid zone, attenuation of the photoreceptors, and deposits within the retinal pigment epithelium. CONCLUSION: A case of deferoxamine-induced maculopathy was described and the use of multimodal retinal imaging to study this disease entity was presented.
Authors: Ruben Jauregui; Karen Sophia Park; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang Journal: Doc Ophthalmol Date: 2018-05-16 Impact factor: 2.379
Authors: Mohamed Belmouhand; Christina Eckmann-Hansen; Tomas Ilginis; Eva Birgitte Leinøe; Bo Kok Mortensen; Michael Larsen Journal: BMC Ophthalmol Date: 2021-07-13 Impact factor: 2.209